Dasatinib News and Research

RSS
Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.
BCR–ABL transcript type linked to TKI response, outcomes

BCR–ABL transcript type linked to TKI response, outcomes

Positive bosutinib response for elderly blast phase CML patient

Positive bosutinib response for elderly blast phase CML patient

Cardiovascular considerations crucial for CML TKI patients

Cardiovascular considerations crucial for CML TKI patients

Leukaemia drug could slow progression of Duchenne muscular dystrophy

Leukaemia drug could slow progression of Duchenne muscular dystrophy

Discovery may lead to potential new therapeutic approach to eradicate blood cancers

Discovery may lead to potential new therapeutic approach to eradicate blood cancers

Comorbidities relevant to CML TKI choice common

Comorbidities relevant to CML TKI choice common

CML arterial adverse events rate dependent on TKI choice

CML arterial adverse events rate dependent on TKI choice

CV risk assessment essential for CML TKI trial design

CV risk assessment essential for CML TKI trial design

Avillion enrolls patients in BFORE Phase III trial to treat chronic myelogenous leukemia

Avillion enrolls patients in BFORE Phase III trial to treat chronic myelogenous leukemia

Researchers identify drugs that may enhance ability of TKI dasatinib to kill human cancer cells

Researchers identify drugs that may enhance ability of TKI dasatinib to kill human cancer cells

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

Rare BCR-ABL fusions highlighted in CML

Rare BCR-ABL fusions highlighted in CML

Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

Patient characteristics may guide TKI use in CML

Patient characteristics may guide TKI use in CML

High CIP2A may guide TKI choice for chronic phase CML

High CIP2A may guide TKI choice for chronic phase CML

CML guidelines highlight need for TKI switch timing, choice

CML guidelines highlight need for TKI switch timing, choice

Fourth-line bosutinib ‘appropriate’ after prior CML treatment failure, intolerance

Fourth-line bosutinib ‘appropriate’ after prior CML treatment failure, intolerance

Researchers identify new class of drugs that slows aging process

Researchers identify new class of drugs that slows aging process

Second-line bosutinib well tolerated by Japanese patients

Second-line bosutinib well tolerated by Japanese patients